A Study to Assess the Tolerability of Oxylanthanum Carbonate in Patients With Chronic Kidney Disease on Dialysis
Trial details
- Registry ID
- NCT06218290
- Drugs studied
- Oxylanthanum Carbonate
TrialRedline tracks 1 clinical trial sponsored by Unicycive Therapeutics, Inc: 1 Phase 2.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| A Study to Assess the Tolerability of Oxylanthanum Carbonate in Patients With Chronic Kidney Disease on DialysisNCT06218290 | Oxylanthanum Carbonate | Completed | 2024-05-29Actual |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2026-06-29Day | Oxylanthanum CarbonateUnicycive Therapeutics, Inc · UNCY | FDA complete response letterComplete response letter | Not specified | Open original sourceRead source excerpt{"application_number": ["NDA 218607"], "letter_date": "06/29/2026", "letter_type": "COMPLETE RESPONSE", "company_name": "Unicycive Therapeutics Inc.", "file_name": "CRL_NDA218607_20260629.pdf"} First seen: 26 Sep 2026 · Evidence last checked: 26 Sep 2026 |
Names as written in the registry records.